Skip to main content
Clinical Trials/NCT07543861
NCT07543861
Recruiting
Phase 1

A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease

University of Michigan1 site in 1 country5 target enrollmentStarted: April 1, 2026Last updated:

Overview

Phase
Phase 1
Status
Recruiting
Enrollment
5
Locations
1
Primary Endpoint
Gait Speed

Overview

Brief Summary

This research is studying the use of a new type of standing desk in a small number of people to learn about the user experience for people with Parkinson's disease. 12 4-hour sessions will be performed to test the primary hypothesis that dynamic standing improves gait function compared to static standing and control sitting. This study has 2 phases. Phase 1 will be an open-label study and Phase 2 will be an in-lab randomized controlled trial pilot study. This is phase 1 of the study.

Detailed Description

For phase 1, participants will attend up to 12 4-hour sessions using the dynamic standing desk. In addition to these sessions, there will be a clinical assessment at baseline and an outcome session (endpoint assessments). In total, there will be up to 14 sessions per participant. All sessions need to be completed within 6 weeks. At the baseline session, clinical measurements will be collected. These measures will be repeated in the outcome session.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
50 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of Parkinson's Disease

Exclusion Criteria

  • Inability to stand or walk without an assistive device
  • History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, or medication side effects
  • Any other history of medical or psychiatric comorbidity, precluding safe participation in the project.
  • History of symptomatic cardiovascular or pulmonary disease
  • History of active rheumatic arthritis
  • History of stroke or other neurologic conditions with significant residual sensorimotor deficits
  • History of disabling chronic pain syndrome requiring narcotic analgesics
  • Evidence of dementia (Mini Mental State Exam (or Montreal Cognitive Assessment test) \<24 and significant impairment in activities of daily living)
  • Venous ulcerative stasis or severe varicosities.
  • Pregnancy as determined by urine pregnancy test prior to DXA procedure in women of childbearing potential.

Arms & Interventions

Dynamic Standing Desk in People with Parkinsons

Experimental

Up to 12 4-hour sessions with the dynamic standing desk completed in the span of 6 weeks.

Intervention: Dynamic Standing Desk (Device)

Outcomes

Primary Outcomes

Gait Speed

Time Frame: Baseline and post-intervention (up to 6 weeks).

Gait speed will be measured during an 8.5-meter forward walking task measured in meters per second.

Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part III

Time Frame: Baseline and post-intervention (up to 6 weeks).

Clinical assessment that measures motor symptoms in Parkinson's Disease. Higher scores indicates more severe symptoms. Scores range from 0-132.

Montreal Cognitive Assessment

Time Frame: Baseline and post-intervention (up to 6 weeks).

Clinical assessment that measures cognition. Higher scores indicate better cognition. Scores range from 0-30.

Timed Up and Go

Time Frame: Baseline and post-intervention (up to 6 weeks).

Clinical assessment that measures the time it takes for a participant to stand from a chair, walk 3 meters, turn around, walk back to the chair and sit back down. Higher time indicates increased motor impairment.

5 Times Sit to Stand

Time Frame: Baseline and post-intervention (up to 6 weeks).

Clinical assessment that measures the time it takes for a participant to sit and stand five times. Higher time indicates increased motor impairment.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Chatkaew Pongmala

Research Investigator

University of Michigan

Study Sites (1)

Loading locations...

Similar Trials